{"data":{"type":"company_profile","id":190067,"entity_id":"wefunder:company:190067","attributes":{"canonical_url":"https://wefunder.com/tibaray","generated_at":"2026-06-23T02:48:19Z","updated_at":"2026-06-23T01:01:49Z","entity_ids":{"company":"wefunder:company:190067","slug":"wefunder:company_slug:tibaray"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-23T02:48:19Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-23T01:01:49Z","as_of":"2026-06-23T02:48:19Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-23T01:01:49Z","as_of":"2026-06-23T02:48:19Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2026-03-05T01:42:43Z","as_of":"2026-06-23T02:48:19Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2026-03-05T01:42:43Z","as_of":"2026-06-23T02:48:19Z","confidence":"medium"}}},"company":{"id":190067,"entity_id":"wefunder:company:190067","slug":"tibaray","name":"TibaRay, Inc.","tagline":"Patented Radiotherapy Technology Designed to Help Cure Cancer in a FLASH™","story":"TibaRay is building an ultra-fast, ultra-precise radiotherapy platform to dramatically improve cancer outcomes while reducing side effects, cost, and treatment time.We are not just improving cancer therapy. We are redefining what is curable.The SolutionTibaRay enables FLASH—delivering treatment in a fraction of a second instead of minutes, over 400X faster than today’s state-of the art technology. Recent research shows that this can greatly reduce normal tissue damage, allowing for more curative treatments. In addition, twice as many patients can be treated at reduced costs.FLASH radiobiology is a new scientific discovery showing that ultra-rapid radiation can spare healthy tissue without compromising tumor kill. TibaRay's advances in accelerator physics, RF systems, and beam control now make conformal FLASH clinically feasible for the first time.The Tech Powering PHASEROver the past decade TibaRay has been developing revolutionary linear accelerator and RF component technologies invented at Stanford University. More than $27 million has been invested, including more than $13 million in non-dilutive highly competitive federal grants. These technologies are commercial today and will power PHASER in the near future.Our Galactica linac has been designed into the Leo Cancer Care treatment system, marking the first TibaRay Inside™ commercial partnership integrating Galactica into Leo’s complete treatment platform.Market OpportunityWe are initially focusing on cancer care and treating patients with tumors anywhere in the body.The cancer therapy market is $300 billion overall with radiotherapy being $9 billion (currently with 6-8% CAGR).In addition, there’s $20 billion in opportunities for applications in other major illnesses:Cardiac arrhythmias (e.g., ventricular tachycardia*, atrial fibrillation)Pulmonary emphysema*Functional neurologic conditionsArthritis \u0026amp; inflammatory conditionsOthers (potentially Alzheimer’s, etc.)…*First human clinical trials of focused radiotherapy performed by Dr. Bill LooBusiness ModelOur near-term revenue will be generated by delivering our linacs into the TibaRay Inside™ markets, including healthcare, non-destructive testing, and border security applications.Our long-term objective is full commercialization and deployment of the PHASER system, leveraging our proprietary accelerator technology to address large global markets and create multi-billion-dollar revenue opportunities.Competitive AdvantageFully integrated facility with:Large radiation-shielded vault (radiation safety approved)Advanced production capabilities with CNCs and hydrogen brazing bonding furnaceAccelerator production QMS compliant with ISO 13485Recent FeaturesJoin our mission to save millions of lives by transforming cancer radiotherapy—making treatment more effective, more accessible, and safer for patients worldwide.","location":"Fremont, CA","website":"https://tibaray.com/","total_amount_raised":329453,"total_investors":138,"is_funded":false,"is_active":true,"quality_score":4,"related_urls":["https://wefunder.com/tibaray","https://tibaray.com/"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/custom_card_photo/190067/xxl_TibaRay__Inc__1776716038278.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/190067/large_TibaRay__Inc__logo_1776716046953.png","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/190067/standard_avatar.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/custom_card_photo/190067/large_TibaRay__Inc__1776716038278.jpg","pitch_deck_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTg0ODMwMiwicHVyIjoiYmxvYl9pZCJ9fQ==--2d9c57d92d67fee55930d3ed806d066c2809661f/TibaRayInvestorDeck_2026-01-05%20(Wefunder).pdf","pitch_deck_filename":"TibaRayInvestorDeck_2026-01-05 (Wefunder).pdf"},"links":{"company_url":"https://tibaray.com/"},"highlights":[{"id":62781,"name":"venture_backed","url":"venturebacked","presentable_name":"VC-Backed","description":"Raised $250K or more from a venture firm","image_url":"https://uploads.wefunder.com/2021/profile-highlights-check.svg"},{"id":75537,"name":"repeat_founder","url":"repeatfounder","presentable_name":"Repeat Founder","description":"Started a prior company with $2M+ in funding or revenue","image_url":"https://uploads.wefunder.com/2021/profile-highlights-replay.svg"}],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"Robust IP portfolio with 20+ issued and pending patents on next-generation radiotherapy technology."},{"index":2,"claim_id":"claim-fact-2","value":"Partnership with an innovative radiotherapy technology provider to integrate core technology."},{"index":3,"claim_id":"claim-fact-3","value":"$9 billion global radiotherapy market with adjacent multi-billion dollar applications."},{"index":4,"claim_id":"claim-fact-4","value":"24,000 sq ft fully integrated Silicon Valley facility for prototyping, testing, and production."},{"index":5,"claim_id":"claim-fact-5","value":"Led by a CEO who built a NASDAQ-listed company to a $2B market cap."},{"index":6,"claim_id":"claim-fact-6","value":"Team of world-class physicists, engineers, and clinical advisors."}],"team":[{"id":6508861,"entity_id":"wefunder:company_role:6508861","user_entity_id":"wefunder:user:4969230","role":"founder","name":"Thinh Tran","title":"CEO \u0026 Director","bio":"Mr. Tran is a Stanford graduate, Founder \u0026amp; CEO of Vita Imaging and Founder \u0026amp; former CEO of Sigma Designs, which he grew from startup to a NASDAQ-listed company with a ~$2B market cap. He brings 40+ years of leadership, capital-raising, and M\u0026amp;A experience.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6508861/square_avatar.jpg?1780441268","profile_url":"https://wefunder.com/thinh.tran.2","personal_url":"https://tibaray.com","related_urls":["https://wefunder.com/thinh.tran.2","https://tibaray.com"]},{"id":6556605,"entity_id":"wefunder:company_role:6556605","user_entity_id":"wefunder:user:5042359","role":"founder","name":"Sami Tantawi","title":"CTO, Co-Founder, Director","bio":"Professor Sami Tantawi is an ASU Physics professor, former Stanford professor, and former SLAC chief scientist. He led world-class RF accelerator research, won the U.S. Particle Accelerator School achievement award, and is an APS Fellow.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6556605/square_avatar.jpg?1780441268","profile_url":"https://wefunder.com/sami.tantawi","personal_url":"https://search.asu.edu/profile/5081646","related_urls":["https://wefunder.com/sami.tantawi","https://search.asu.edu/profile/5081646"]},{"id":6556606,"entity_id":"wefunder:company_role:6556606","role":"founder","name":"Bill Loo, MD, PhD","title":"Chief Medical Advisor, Co-Founder, Director","bio":"Billy W. Loo Jr., MD PhD is a Stanford Professor and Director of Thoracic Radiation Oncology, a global leader in lung cancer radiotherapy, FLASH therapy, and proton therapy, and co-inventor of PHASER, a breakthrough ultra-precise cancer therapy.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6556606/square_blob.jpg?1780441268","personal_url":"https://med.stanford.edu/profiles/Billy_Loo","related_urls":["https://med.stanford.edu/profiles/Billy_Loo"]},{"id":6556607,"entity_id":"wefunder:company_role:6556607","user_entity_id":"wefunder:user:5034586","role":"founder","name":"Peter Maxim","title":"Co-Founder, Director","bio":"Peter Maxim is Professor and Vice-Chair of Medical Physics at UC Irvine and Co-founder of TibaRay. A leader in SABR and ultra-fast FLASH radiation, he holds multiple patents, major AAPM awards, and is advancing sub-second curative radiotherapy worldwide.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6556607/square_blob.jpg?1780441268","profile_url":"https://wefunder.com/peter.maxim","personal_url":"https://faculty.uci.edu/profile/?facultyId=7264","related_urls":["https://wefunder.com/peter.maxim","https://faculty.uci.edu/profile/?facultyId=7264","https://www.tibaray.com"]},{"id":6589817,"entity_id":"wefunder:company_role:6589817","role":"founder","name":"Rebecca Fahrig","title":"Co-Founder","bio":"Rebecca Fahrig, PhD, is a pioneer in x-ray imaging and cone-beam CT. Former Stanford Radiology faculty, now VP of Innovations at Siemens Healthcare, leading 50 scientists developing next-gen image guidance systems.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6589817/square_avatar.jpg?1780441268","linkedin_url":"https://linkedin.com/in/rebecca-fahrig/","related_urls":[]},{"id":6630850,"entity_id":"wefunder:company_role:6630850","user_entity_id":"wefunder:user:5068301","role":"employee","name":"Khalil Doheny","avatar_url":"https://wefunder.com/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTYxMjQwMSwicHVyIjoiYmxvYl9pZCJ9fQ==--4c1fc0c3c386c9fd7c3a49888738ec0e330dc33c/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGVnIiwicmVzaXplX3RvX2ZpbGwiOlsxNTAsMTUwXX0sInB1ciI6InZhcmlhdGlvbiJ9fQ==--0ef6870c9fa05ea1e6ca6f7ebb7d4a5157059dbc/profile_picture_ac0d622c8842.jpeg?1780441269","profile_url":"https://wefunder.com/khalil.doheny.1","related_urls":["https://wefunder.com/khalil.doheny.1"]},{"id":6714751,"entity_id":"wefunder:company_role:6714751","user_entity_id":"wefunder:user:5117577","role":"founder","name":"Bill Loo, Md, PhD","title":"Founder","avatar_url":"https://uploads.wefunder.com/2021/user_default_icon_circle.png?1780526847","profile_url":"https://wefunder.com/bill.loo.md.phd","related_urls":["https://wefunder.com/bill.loo.md.phd"]},{"id":6714862,"entity_id":"wefunder:company_role:6714862","user_entity_id":"wefunder:user:5117581","role":"employee","name":"Dzung Wright","avatar_url":"https://uploads.wefunder.com/2021/user_default_icon_circle.png?1780526847","profile_url":"https://wefunder.com/dzung.wright","related_urls":["https://wefunder.com/dzung.wright"]}],"featured_investors":[{"id":13113,"entity_id":"wefunder:company_investor_profile:13113","investor_profile_id":4238419,"investor_profile_entity_id":"wefunder:investor_profile:4238419","subject_entity_id":"wefunder:user:4747224","name":"Tuoc Luong","role_title":"","bio":"https://www.linkedin.com/in/tuocluong/","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTMxMjc4MSwicHVyIjoiYmxvYl9pZCJ9fQ==--8bcd8124b97af8ac8a9e281c5c13d216fe998de3/filename","profile_url":"https://wefunder.com/tuoc.luong","endorsement_quote":"I have 3 investment thesis: 1) Innovative Technology and a moat that is difficult for competitors to cross 2) Does the technology and product provide a benefit for society. Tibaray has both of these qualities. 3) Does the company have the right leader and team to succeed. I think the CEO Thinh Tran has the experience of taking a company from startup to IPO and further (he has shown this in the past). From a technology perspective there are some big name professors from Stanford who are the leading experts in their fields. So Tibaray has the team, the technology moat and what it does benefit society. Love it!","endorsement_name":"","investment_total":605000,"investment_info":"Invested $5,000 this round \u0026 $600,000 previously","is_lead_investor":true,"related_urls":["https://wefunder.com/tuoc.luong"]},{"id":13391,"entity_id":"wefunder:company_investor_profile:13391","investor_profile_id":4580358,"investor_profile_entity_id":"wefunder:investor_profile:4580358","subject_entity_id":"wefunder:notable_investor:17379","name":"William Wraith III \u0026 Family","role_title":"","bio":"William Wraith III - Chairman and CEO, The Wraith Group, Inc. Serial Entrepreneur \u0026amp; Philanthropist","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTcyNDk2MSwicHVyIjoiYmxvYl9pZCJ9fQ==--a61f384f02e571391cff6a611174018cfc2acdbe/avatar.jpg","profile_url":"https://wefunder.com/the.wraith.family","endorsement_quote":"\"I invest in technologies that have the potential to save millions of lives by defeating the worst of Cancer, Lung, and Cardiovascular diseases—TibaRay's breakthrough in affordable 'FLASH Radiation' being one of the most compelling lifesaving innovations I’ve seen and had the privilege of supporting. Having helped finance Accuray in its early days of bringing CyberKnife to market, I’ve witnessed firsthand how breakthrough innovations in radiation therapy can redefine cancer care. TibaRay represents the next major leap forward—advancing FLASH radiotherapy with the potential to make such treatment dramatically faster, more precise, and far more accessible to patients worldwide. What drives my investment is simple: the opportunity to help bring to market a technology that is fundamentally transforming how we fight cancer. TibaRay combines a world-class team with a bold and clear vision, and a truly differentiated platform with the potential to deliver clinical impacts at a global scale never before possible.\" Bill Wraith III, teaming with sons Steve and Bill IV, has initiated over $300 million in private funding for innovative startups, playing pivotal leadership roles as Chairman, Co-Founder, Lead Funder, and Adviser in advancing next-generation medical and new materials technologies, including FLASH radiotherapy initiatives through his investments in TibaRay. A graduate of Stanford University (BS, MS, MBA), Bill is the recipient of Stanford’s prestigious Gold Spike, the university's highest award for volunteer leadership—recognizing his contributions to funding and lifetime of commitment to advancing research, medicine, and education. In the early 2000's, Bill was awarded an Honorary Doctor of Science degree by the California College of Podiatric Medicine, honoring his leadership, as Chairman of the Board of Trustees, for leading its reorganization, including first endowment funding and merger with Samuel Merritt University in Oakland.","endorsement_name":"","investment_total":1677197,"investment_info":"Invested $400,000 this round \u0026 $1,277,197 previously","is_lead_investor":false,"related_urls":["https://wefunder.com/the.wraith.family"]}],"investor_memos":[],"tab_counts":{"posts":0,"ask_questions":10,"featured_investors":2,"faq_entries":5},"active_fundraises":[{"id":151775,"entity_id":"wefunder:fundraise:151775","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"ttw","security_type":"","currency":"USD","testing_the_waters":true,"min_purchase":500,"max_purchase":9,"funding_target":5000000.0,"minimum_target":"50000.0","maximum_target":"5000000.0"},{"id":151774,"entity_id":"wefunder:fundraise:151774","state":"open","offering_type":"4(a)(6)","funding_type":"note","structure":"equity","security_type":"equity","currency":"USD","testing_the_waters":false,"min_purchase":500,"max_purchase":9,"funding_target":5000000.0,"minimum_target":"50000.0","maximum_target":"5000000.0","funding_started_at":"2026-03-03T22:49:09Z","funding_closed_at":"2026-09-01T03:59:59Z"}],"latest_fundraise":{"id":151775,"entity_id":"wefunder:fundraise:151775","state":"successful","offering_type":"4(a)(6)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null,"terms":{"eb":"$54M","nb":"$60M","txt":"pre-money valuation"}},"recent_posts":[],"q_and_a":[{"id":331672,"entity_id":"wefunder:comment:331672","question":"What are the relationships between \"Vita Imaging\" and \"TibaRay\" financially, physically, legally, and control wise? How large are the engineering teams? Operations teams? Have either of these groups integrated, qualified, or produced anything? I see a lot of concept and pontificating but not much melon here. How do you arrive at a $54M valuation? Do you have pre-orders? Prototypes? Proof of Concept? Characterization testing? UL or CE testing? Do you have hazard assessments? Approval from the Laser Safety Board? What is your certification plan?","author_name":"William Kaake","votes":3,"created_at":"2026-04-21T21:55:10Z","canonical_url":"https://wefunder.com/tibaray#question-331672","answers":[{"id":331902,"entity_id":"wefunder:comment:331902","answer":"Great questions—happy to clarify. Vita Imaging and TibaRay are separate companies with no shared ownership or finances. I lead both, but each has its own team, investors, and operations. Strategically, they are complementary: Vita focuses on cancer detection, while TibaRay focuses on treatment. We have dedicated engineering and operations teams working on real hardware and systems—not just concepts. This includes active development, testing, and integration work. We are well beyond the concept stage. We have an active partnership with Leo Cancer Care for system integration, along with working prototypes and subsystems that have already been developed and tested. We are now moving into commercial deployment with orders from Leo Cancer Care : https://www.prnewswire.com/news-releases/leo-cancer-care-plans-to-integrate-tibaray-linacs-into-future-grace-photon-therapy-platform-302574928.html On the regulatory side, we are following a standard medical device pathway. Our quality system is aligned with ISO 13485, and we are working toward FDA (510K) clearance Our $54M valuation reflects several factors: the maturity and platform nature of our technology, strategic partnerships, the size of the radiation therapy market, as well as the $27M already invested in the company and over 12 years of development. For context, complex medical devices often require multi-year development cycles and significant capital to reach commercialization . In short, this is not just a concept—we have real technology, real partners, and a clear path to commercialization.","author_name":"Thinh Tran","votes":3,"created_at":"2026-04-23T23:14:37Z"}]},{"id":331827,"entity_id":"wefunder:comment:331827","question":"thanks for swift response! Saturday morning I am making a ton of business investments. few more questions what is your moat? there is a company raising now called CancerVax(stood out to me) I can't tell between you and them which is better. can you tell me the key difference between you and them?what they say sounds amazing too and investors are taking notice they raised a ton. I do like that your valuation is a lot less. you both are saying we are doing this or that and nobody else is. you both do an amazing job explaining things. thanks for your time!","author_name":"John Webster","votes":1,"created_at":"2026-04-23T15:22:32Z","canonical_url":"https://wefunder.com/tibaray#question-331827","answers":[{"id":331903,"entity_id":"wefunder:comment:331903","answer":"Great question—and you’re right, both stories sound compelling. The key difference is that we are solving different problems: - TibaRay: advanced radiation platform (hardware + physics) to directly treat tumors - CancerVax: early-stage biotech developing a cancer vaccine to train the immune system Our moat is in deep engineering and system integration—building high-performance linacs, manufacturing them, and integrating into clinical systems. This is very hard to replicate and has a clearer path to near-term deployment. CancerVax is exciting, but it’s pre-clinical biotech, which typically carries longer timelines and higher scientific risk . Simple way to think about it: - They are betting on a biological breakthrough - We are delivering a next-generation upgrade to an existing standard of care (radiation) Both could succeed—but our approach is more near-term, execution-driven, and infrastructure-based, which is why some investors see it as lower risk (and currently at a lower valuation, potentially higher return for investors).","author_name":"Thinh Tran","votes":1,"created_at":"2026-04-23T23:36:12Z"}]},{"id":331674,"entity_id":"wefunder:comment:331674","question":"If this entity is losing over $3M per year, when do you plan to become profitable?","author_name":"William Kaake","votes":1,"created_at":"2026-04-21T22:04:23Z","canonical_url":"https://wefunder.com/tibaray#question-331674","answers":[{"id":331901,"entity_id":"wefunder:comment:331901","answer":"Hello William: In our space, it’s normal to operate at a loss during the development phase—medical device companies typically take 3–7+ years to mature R\u0026amp;D due to technical complexity as well as regulatory and clinical requirements . The key difference with TibaRay is that we have already largely de-risked the core technology and are now transitioning into commercial deployment through partners and early systems. With commercialization underway, our focus is on scaling revenue, with the goal of reaching profitability within the next two years. Thinh CEO, Tibaray","author_name":"Thinh Tran","votes":4,"created_at":"2026-04-23T22:52:52Z"}]},{"id":331610,"entity_id":"wefunder:comment:331610","question":"What is the exit plan (acquisition, IPO, merger, etc.) in which investors will be able to see a ROI?","author_name":"bugg logg","votes":1,"created_at":"2026-04-21T13:18:52Z","canonical_url":"https://wefunder.com/tibaray#question-331610","answers":[{"id":331665,"entity_id":"wefunder:comment:331665","answer":"Hi bugg log : Thank you for the question—this is an important consideration. Our primary focus is to bring our product to market successfully and build a sustainable, profitable company. By demonstrating real clinical value and commercial traction, we believe this will naturally open the door to multiple exit opportunities over time. As we scale, this could include a potential IPO or a strategic merger or acquisition with a major player in the radiotherapy or medical device space. Historically, companies that establish strong technology and market position in this sector have attracted significant strategic interest. The global radiotherapy/Imaging market is dominated by a small number of large players (e.g., Varian/Siemens, Elekta, Accuray, GE Healthcare , Philips ), and historically, these companies have acquired innovative technologies that can materially improve treatment outcomes or expand their product portfolios. We believe TibaRay’s FLASH-enabled linac platform fits well within this pattern. In short, our strategy is to: • Execute and commercialize our technology • Build a strong, profitable business • Create optionality for IPO or M\u0026amp;A as the company matures We believe this approach provides the best path to maximizing long-term value for investors. Best regards, Thinh CEO, Tibaray","author_name":"Thinh Tran","votes":2,"created_at":"2026-04-21T21:17:19Z"}]},{"id":335967,"entity_id":"wefunder:comment:335967","question":"Based on TibaRay's 10 MV LA technology, why Leo Cancer Caner's Grace* system is only 6 MV with 1200 cGy/min?","author_name":"Lee Vincent","votes":0,"created_at":"2026-06-19T14:01:53Z","canonical_url":"https://wefunder.com/tibaray#question-335967","answers":[{"id":335973,"entity_id":"wefunder:comment:335973","answer":"Thank you for the question. We cannot comment on Leo Cancer Care’s specific marketing, product, or regulatory strategy for the Grace system. However, the current Grace specification should not be viewed as the technical limit of TibaRay’s LINAC technology. TibaRay’s accelerator platform is capable of producing much higher energy levels and higher dose rates, including 10 MV-class configurations and future ultra-high dose-rate applications. In short, Leo’s initial Grace configuration appears to be an initial product specification, while TibaRay’s LINAC platform is designed to be scalable for higher-performance applications. Best, Thinh","author_name":"Thinh Tran","votes":2,"created_at":"2026-06-19T16:10:06Z"}]},{"id":335188,"entity_id":"wefunder:comment:335188","question":"Good afternoon. Just a few questions, please: 1. I see minimal revenues on the Form C. Are these from your partnership with Leo Cancer Care? 2. Your campaign was awarded the “VC-Backed” label, but I don’t see any mention of capital raised from a venture firm — only notable mention is IHH. Have you raised any funds from a VC? If so, who? 3. Why do you believe your company is in position to succeed right now? In other words, what makes now the right time for a company like TibaRay to emerge? Thanks!","author_name":"Brian Eller","votes":0,"created_at":"2026-06-08T17:42:13Z","canonical_url":"https://wefunder.com/tibaray#question-335188","answers":[{"id":335346,"entity_id":"wefunder:comment:335346","answer":"1. The minimal revenues reflected in the Form C are not from Leo Cancer Care. They are primarily from deliveries to research institutions and revenue associated with grants . 2. Yes, TibaRay has received investment from venture and institutional investors. IHH Healthcare is an institutional strategic investor in the Leo/TibaRay ecosystem rather than a traditional venture fund, . In addition, we have raised capital from other sophisticated investors, including Wexford Capital and other accredited investors. The “VC-Backed” label reflects that TibaRay has raised funds from institutional and venture-style investors, although our financing history has also included individual accredited investors, strategic investors, grants, and convertible notes.","author_name":"Thinh Tran","votes":0,"created_at":"2026-06-10T21:33:28Z"},{"id":335383,"entity_id":"wefunder:comment:335383","answer":"Hello Brian,Thank you for the thoughtful questions. TibaRay is positioned to succeed now because the market is ready for a new generation of radiation therapy technology.Radiation therapy has improved in imaging, targeting, and treatment planning, but the core LINAC platform has not fundamentally changed in decades. Hospitals need systems that are more compact, affordable, faster, and capable of supporting future FLASH therapy.TibaRay is not starting from scratch. Our technology is built on years of work from Stanford, SLAC, and our founding team, with a strong IP position and deep accelerator expertise.We also have a clear commercialization path: first integrating a single TibaRay LINAC into Leo Cancer Care’s upright treatment platform, then advancing toward a multi-LINAC array for FLASH therapy.At the same time, while the FLASH market matures and the required clinical trials are completed, TibaRay is also targeting commercial markets outside of healthcare, including border security, non destructive testing and other radiation-based applications.In short, now is the right time because the clinical need, market demand, FLASH opportunity, non-healthcare commercial applications, and TibaRay’s technology platform are all coming together.","author_name":"Lisa S.","votes":0,"created_at":"2026-06-11T14:59:13Z"}]},{"id":334988,"entity_id":"wefunder:comment:334988","question":"What is the exit plan (acquisition, IPO, merger, etc.) in which investors will be able to see a ROI?","author_name":"bugg logg","votes":0,"created_at":"2026-06-05T00:36:59Z","canonical_url":"https://wefunder.com/tibaray#question-334988","answers":[{"id":334995,"entity_id":"wefunder:comment:334995","answer":"TibaRay’s goal is to build a significant and profitable independent company in next-generation radiation therapy and related accelerator applications. We believe the best way to create investor value is to build a real business with strong technology, customer demand, strategic partnerships, and a clear path to revenue and profitability. At the same time, we recognize that investors ultimately need a path to liquidity and ROI. Our current expectation is that a potential exit opportunity could occur within approximately three years, assuming we are able to achieve key milestones, including product integration, regulatory progress, early revenue, profitability progress, and broader market validation. This is not a guarantee, but it reflects our current planning horizon and the level of strategic interest we believe could develop as the company advances. The most likely exit opportunities could include a strategic acquisition, merger, or partnership with a major medical technology or radiation oncology company. An IPO could also be a possibility if TibaRay reaches the right scale, revenue growth, and market visibility. Our focus now is to increase company value by advancing the technology toward commercialization, building a profitable business, securing strategic partnerships, and demonstrating revenue opportunities in both medical and non-medical applications.","author_name":"Thinh Tran","votes":1,"created_at":"2026-06-05T01:35:45Z"}]},{"id":333038,"entity_id":"wefunder:comment:333038","question":"Hi my name is Sherwood Neiss. I'm managing partner at D3VC.ai. We are an early-stage venture fund that invests in select RegCF offerings. Yours scored high on our algorithm and we had a chance to look at your offering during our last investment committee meeting. Our team had the following questions we were hoping you could answer: 1. FDA Clearance Phase and Timeline: What phase of FDA clearance are you currently in for your flash radiotherapy platform? Can you provide details on your clinical trial status and expected timeline to market? 2. Healthy Tissue Sparing Mechanism: How are you able to spare healthy tissue while maintaining equivalent tumor kill rates? Can you explain the technical details of how your flash radiotherapy achieves this focused treatment approach? 3. Clinical Trial Status and Regulatory Risk: What are the key milestones and timelines for your clinical trials? What regulatory risks do you foresee in the FDA clearance process, and how are you mitigating them? 4. Partnership and Validation Details: Can you provide more information about your partnership that has validated your technology? How does this partnership support your path to FDA clearance and commercialization? Regards, Sherwood","author_name":"Sherwood Neiss","votes":0,"created_at":"2026-05-05T19:40:13Z","canonical_url":"https://wefunder.com/tibaray#question-333038","answers":[{"id":333042,"entity_id":"wefunder:comment:333042","answer":"Hi Sherwood, Thank you for your thoughtful questions and for reviewing TibaRay through your investment committee. We appreciate the interest from D3VC.ai. Below are our responses: - FDA Clearance Phase and Timeline TibaRay is currently commercializing its linear accelerator technology as a core radiation component within an integrated radiotherapy system, rather than as a standalone FLASH treatment platform. Our near-term regulatory path is tied to system-level integration with our clinical partner, Leo Cancer Care. Leo Cancer Care is currently completing its 510(k) FDA clearance for its Grace Photon Therapy Platform , which is expected later this year. We plan to pursue our own 510(k) FDA clearance when we deploy our first complete commercial system in a conventional radiotherapy configuration, with FLASH capability representing the next phase of development and clinical validation. - Healthy Tissue Sparing Mechanism FLASH radiotherapy involves delivering radiation at ultra-high dose rates in extremely short timeframes. Preclinical studies have shown that this approach may reduce damage to normal tissue while maintaining tumor control. The exact biological mechanisms are still under active scientific investigation, but leading hypotheses include differences in oxygen depletion, free radical chemistry, immune response, and normal tissue repair pathways. TibaRay’s technology is designed to enable the ultra-high dose rates and beam control required to translate the FLASH effect into a practical clinical system. - Clinical Trial Status and Regulatory Risk FLASH radiotherapy remains an emerging field, and clinical validation is still required before broad therapeutic claims can be made. Key milestones include completion of system integration, verification and validation testing, partner-site deployment, clinical protocol development, and regulatory submission. The primary regulatory risks relate to the novelty of FLASH dose delivery, the need to demonstrate safety and efficacy, and the integration of multiple subsystems into a complete treatment platform. We are mitigating these risks through a staged commercialization strategy, maintaining a quality system aligned with medical device requirements, working with experienced clinical and regulatory partners, and initially leveraging conventional radiotherapy workflows before expanding into FLASH-specific indications. - Partnership and Validation Details TibaRay is partnered with Leo Cancer Care to provide our Galactica linear accelerator technology as the X-ray radiation component for Leo’s upright radiotherapy system : https://www.prnewswire.com/news-releases/leo-cancer-care-plans-to-integrate-tibaray-linacs-into-future-grace-photon-therapy-platform-302574928.html . This partnership provides important commercial and technical validation by placing TibaRay’s linac technology into a real clinical system architecture with a defined path to commercialization. The first deployment is expected to be at Mayo Clinic. In addition, TibaRay’s technology is built on foundational research from Stanford/SLAC and advanced accelerator expertise from our co-founders, Dr. Bill Loo of Stanford and Dr. Sami Tantawi, a long-time SLAC accelerator physicist. This combination of clinical leadership and accelerator physics is central to our differentiation. In summary, TibaRay’s strategy is to enter the market through practical linac commercialization and system integration, while building toward our broader vision of scalable photon FLASH radiotherapy. Thinh","author_name":"Thinh Tran","votes":2,"created_at":"2026-05-05T20:58:16Z"}]},{"id":332092,"entity_id":"wefunder:comment:332092","question":"What is the anticipated system sales price per unit, and how does this compare to currently available (traditional) systems? thx","author_name":"Roy Pascal","votes":0,"created_at":"2026-04-26T19:57:17Z","canonical_url":"https://wefunder.com/tibaray#question-332092","answers":[{"id":332752,"entity_id":"wefunder:comment:332752","answer":"Hello Roy: Today, we primarily provide the linac ( linear a ccelerator ) as a core component within a broader radiation therapy system, so pricing is structured at the subsystem level and varies depending on configuration, integration, and volume. As we evolve toward delivering a complete x-ray treatment system, we expect to capture significantly more value at the system level rather than just the component level. In general, linacs represent a meaningful portion of the overall system cost, and our strategy is to both expand margins and increase total revenue per installation as we move up the stack. Thinh","author_name":"Thinh Tran","votes":2,"created_at":"2026-05-01T01:22:50Z"}]},{"id":331626,"entity_id":"wefunder:comment:331626","question":"I am wondering what makes you different then other companies saying they can help cure cancer that is raising now? is anybody on your team fully committed to this company? out of 3 I see. 2 are college professors and one is a founder and CEO of his own company.","author_name":"John Webster","votes":0,"created_at":"2026-04-21T15:48:13Z","canonical_url":"https://wefunder.com/tibaray#question-331626","answers":[{"id":331662,"entity_id":"wefunder:comment:331662","answer":"Hi John, Thank you for the thoughtful question—this is an important point, and I’m glad you raised it. What differentiates TibaRay is that we are not approaching cancer treatment as a concept—we are building the core enabling technology for next-generation radiotherapy. Specifically, our proprietary linear accelerator platform is designed to deliver ultra-high dose rate (FLASH) radiation, which has the potential to significantly reduce damage to healthy tissue while maintaining tumor control. This represents a fundamentally different approach, not just an incremental improvement. Our strategy is also highly focused and execution-driven. We are working with established partners, including Leo Cancer Care, to integrate our linac into real clinical systems. With Leo, our linac is expected to be used on real patients later this year, which is a key step toward validation and commercialization. Regarding the team, while some of our co-founders hold academic positions, they are deeply involved in the company and are among the leading experts in this field. Their roles at institutions like Stanford are a strength—they provide access to cutting-edge research, clinical insight, and validation. In short, we combine: breakthrough technology (FLASH-enabled linac platform, deep clinical and academic expertise and clear path to real-world deployment and commercialization From an operational standpoint, I am deeply committed to both TibaRay and Vita Imaging, driven by a singular mission: to improve cancer care—from early detection to treatment. Vita Imaging focuses on detecting cancer early, while TibaRay is focused on treating cancer more effectively, particularly through next-generation radiotherapy. I see these not as competing priorities, but as complementary parts of the same mission. On a day-to-day basis, my role is centered on strategy, partnerships, fundraising, and key technical direction for both companies.. Execution is supported by dedicated teams in each organization, including engineering, operations, and clinical collaborators, ensuring that both companies move forward with focus and momentum. I’d be happy to discuss this further if helpful. Best regards, Thinh CEO, Tibaray","author_name":"Thinh Tran","votes":3,"created_at":"2026-04-21T21:05:59Z"}]}],"faq":[{"question":"What is the exit plan (acquisition, IPO, merger, etc.) in which investors will be able to see a ROI?","answer":"Hi bugg log : Thank you for the question—this is an important consideration. Our primary focus is to bring our product to market successfully and build a sustainable, profitable company. By demonstrating real clinical value and commercial traction, we believe this will naturally open the door to multiple exit opportunities over time. As we scale, this could include a potential IPO or a strategic merger or acquisition with a major player in the radiotherapy or medical device space. Historicall..."},{"question":"I am wondering what makes you different then other companies saying they can help cure cancer that is raising now? is anybody on your team fully committed to this company? out of 3 I see. 2 are college professors and one is a founder and CEO of his own company.","answer":"Hi John, Thank you for the thoughtful question—this is an important point, and I’m glad you raised it. What differentiates TibaRay is that we are not approaching cancer treatment as a concept—we are building the core enabling technology for next-generation radiotherapy. Specifically, our proprietary linear accelerator platform is designed to deliver ultra-high dose rate (FLASH) radiation, which has the potential to significantly reduce damage to healthy tissue while maintaining tumor control...."},{"question":"What are the relationships between \"Vita Imaging\" and \"TibaRay\" financially, physically, legally, and control wise? How large are the engineering teams? Operations teams? Have either of these groups integrated, qualified, or produced anything? I see a lot of concept and pontif...","answer":"Great questions—happy to clarify. Vita Imaging and TibaRay are separate companies with no shared ownership or finances. I lead both, but each has its own team, investors, and operations. Strategically, they are complementary: Vita focuses on cancer detection, while TibaRay focuses on treatment. We have dedicated engineering and operations teams working on real hardware and systems—not just concepts. This includes active development, testing, and integration work. We are well beyond the concep..."},{"question":"If this entity is losing over $3M per year, when do you plan to become profitable?","answer":"Hello William: In our space, it’s normal to operate at a loss during the development phase—medical device companies typically take 3–7+ years to mature R\u0026amp;D due to technical complexity as well as regulatory and clinical requirements . The key difference with TibaRay is that we have already largely de-risked the core technology and are now transitioning into commercial deployment through partners and early systems. With commercialization underway, our focus is on scaling revenue, with the g..."},{"question":"thanks for swift response! Saturday morning I am making a ton of business investments. few more questions what is your moat? there is a company raising now called CancerVax(stood out to me) I can't tell between you and them which is better. can you tell me the key difference b...","answer":"Great question—and you’re right, both stories sound compelling. The key difference is that we are solving different problems: - TibaRay: advanced radiation platform (hardware + physics) to directly treat tumors - CancerVax: early-stage biotech developing a cancer vaccine to train the immune system Our moat is in deep engineering and system integration—building high-performance linacs, manufacturing them, and integrating into clinical systems. This is very hard to replicate and has a clearer p..."}]}}}